\
&
Contact us
\
&
Contact us
Published on | 4 years ago
Programmes Digital Europe European Digital Innovation HubsThe European Commission has opened a call for tender for the Digital Transformation Accelerator for the Network of European Digital Innovation Hubs (EDIHs). Submission of a tender is possible until 4 March 2022.
The Digital Transformation Accelerator (DTA) will support the network of European Digital Innovation Hubs (EDIH), with the core objective to accelerate the digital transformation of the European economy, providing services such as community building and training, connection to relevant initiatives, providing to interested EDIHs the possibility to engage with regional, national and European relevant initiatives, collection and analysis of the key performance indicators (KPI) defined for the EDIH, external communication, and management of the interactive catalogue of European Digital Innovation Hubs and other digital capacities funded by the Digital Europe Programme.
The relevant documents for this procurement consist of the contract notice, an invitation letter, the draft contract(s) and tender specifications with their respective annexes. All documents are available at the following: https://etendering.ted.europa.eu/cft/cft-display.html?cftId=7791
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
